BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, Jones O, Palmer DH, Cox TF, Smith CJ, O'Reilly DA, Izbicki JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Padbury R, Shannon J, Dervenis C, Glimelius B, Deakin M, Anthoney A, Lerch MM, Mayerle J, Oláh A, Rawcliffe CL, Campbell F, Strobel O, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Ann Surg 2019;269:520-9. [PMID: 29068800 DOI: 10.1097/SLA.0000000000002557] [Cited by in Crossref: 95] [Cited by in F6Publishing: 48] [Article Influence: 31.7] [Reference Citation Analysis]
Number Citing Articles
1 Leonhardt CS, Traub B, Hackert T, Klaiber U, Strobel O, Büchler MW, Neoptolemos JP. Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. Journal of Pancreatology 2020;3:1-11. [DOI: 10.1097/jp9.0000000000000040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
2 Neoptolemos JP, Jones RP, Büchler MW. Recurrence After Resection of Pancreatic Ductal Adenocarcinoma-Reply. JAMA Surg 2020;155:362-3. [PMID: 31895438 DOI: 10.1001/jamasurg.2019.5465] [Reference Citation Analysis]
3 Carrasco-garcia E, Lopez L, Moncho-amor V, Carazo F, Aldaz P, Collado M, Bell D, Gaafar A, Karamitopoulou E, Tzankov A, Hidalgo M, Rubio Á, Serrano M, Lawrie CH, Lovell-badge R, Matheu A. SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. Cancers 2022;14:916. [DOI: 10.3390/cancers14040916] [Reference Citation Analysis]
4 Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919875568. [PMID: 31598142 DOI: 10.1177/1758835919875568] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 15.3] [Reference Citation Analysis]
5 Pereira SP, Oldfield L, Ney A, Hart PA, Keane MG, Pandol SJ, Li D, Greenhalf W, Jeon CY, Koay EJ, Almario CV, Halloran C, Lennon AM, Costello E. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 2020;5:698-710. [PMID: 32135127 DOI: 10.1016/s2468-1253(19)30416-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 22.0] [Reference Citation Analysis]
6 Tanaka M, Inoue Y, Matsueda K, Hiratsuka M, Muto M, Kawakatsu S, Ono Y, Mise Y, Ishizawa T, Ito H, Takahashi Y, Takazawa Y, Saiura A. Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer. J Gastrointest Surg 2020;24:619-26. [PMID: 30937709 DOI: 10.1007/s11605-019-04203-2] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Cai B, Lu Z, Neoptolemos JP, Diener MK, Li M, Yin L, Gao Y, Wei J, Chen J, Guo F, Tu M, Xi C, Wu J, Gao W, Dai C, Jiang K, Büchler MW, Miao Y. Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. Langenbecks Arch Surg 2021;406:691-701. [PMID: 33507403 DOI: 10.1007/s00423-021-02080-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 van Hilst J, Korrel M, Lof S, de Rooij T, Vissers F, Al-Sarireh B, Alseidi A, Bateman AC, Björnsson B, Boggi U, Bratlie SO, Busch O, Butturini G, Casadei R, Dijk F, Dokmak S, Edwin B, van Eijck C, Esposito A, Fabre JM, Falconi M, Ferrari G, Fuks D, Groot Koerkamp B, Hackert T, Keck T, Khatkov I, de Kleine R, Kokkola A, Kooby DA, Lips D, Luyer M, Marudanayagam R, Menon K, Molenaar Q, de Pastena M, Pietrabissa A, Rajak R, Rosso E, Sanchez Velazquez P, Saint Marc O, Shah M, Soonawalla Z, Tomazic A, Verbeke C, Verheij J, White S, Wilmink HW, Zerbi A, Dijkgraaf MG, Besselink MG, Abu Hilal M; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS). Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Trials 2021;22:608. [PMID: 34503548 DOI: 10.1186/s13063-021-05506-z] [Reference Citation Analysis]
9 Goyal SP, Vojnic M, Yang JI, Jose J, Newman E, Saif MW. Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do? J Cell Signal 2021;2:80-4. [PMID: 34355216 DOI: 10.33696/signaling.2.037] [Reference Citation Analysis]
10 Liu B, Wu J, Li C, Li Y, Qiu H, Lv A, Liu Q, Liu D, Wang Z, Hao C. The role of coeliac axis resection in resected ductal adenocarcinoma of the distal pancreas: A result of tumour topography or a prognostic factor? Pancreatology 2021:S1424-3903(21)00612-8. [PMID: 34764022 DOI: 10.1016/j.pan.2021.11.001] [Reference Citation Analysis]
11 Kopetskyi VI, Kopchak KV, Cheverdiuk DO, Kvasivka OO, Beznosenko AP, Kolesnik OO, Gushchin VV. Establishing of Peritoneal Surface Malignancy Treatment Program: Background in Ukraine, Patient Selection, Staff Schedule, Perioperative Outcomes of First 28 Patients. Indian J Surg Oncol 2020;11:263-7. [PMID: 32523273 DOI: 10.1007/s13193-020-01056-z] [Reference Citation Analysis]
12 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Crippa S, Belfiori G, Tamburrino D, Partelli S, Falconi M. Indications to total pancreatectomy for positive neck margin after partial pancreatectomy: a review of a slippery ground. Updates Surg 2021;73:1219-29. [PMID: 34331677 DOI: 10.1007/s13304-021-01141-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020;17:108-123. [PMID: 31705130 DOI: 10.1038/s41571-019-0281-6] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 26.3] [Reference Citation Analysis]
15 Acher AW, Bleicher J, Cannon A, Scaife C. Advances in surgery for pancreatic cancer. J Gastrointest Oncol 2018;9:1037-43. [PMID: 30603122 DOI: 10.21037/jgo.2018.05.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kamachi H, Tsuruga Y, Orimo T, Wakayama K, Shimada S, Nagatsu A, Yokoo H, Kamiyama T, Katoh N, Taketomi A. R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy. In Vivo 2018;32:1183-91. [PMID: 30150442 DOI: 10.21873/invivo.11362] [Reference Citation Analysis]
17 Schwarz L, Vernerey D, Bachet JB, Tuech JJ, Portales F, Michel P, Cunha AS. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer 2018;18:762. [PMID: 30041614 DOI: 10.1186/s12885-018-4663-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
18 Kang JS, Choi YJ, Byun Y, Han Y, Kim JH, Lee JM, Sohn HJ, Kim H, Kwon W, Jang JY. Radiological tumour invasion of splenic artery or vein in patients with pancreatic body or tail adenocarcinoma and effect on recurrence and survival. Br J Surg 2021:znab357. [PMID: 34718433 DOI: 10.1093/bjs/znab357] [Reference Citation Analysis]
19 Vuijk FA, de Muynck LDAN, Franken LC, Busch OR, Wilmink JW, Besselink MG, Bonsing BA, Bhairosingh SS, Kuppen PJK, Mieog JSD, Sier CFM, Vahrmeijer AL, Verheij J, Fariňa-Sarasqueta A, Swijnenburg RJ. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Sci Rep 2020;10:16211. [PMID: 33004930 DOI: 10.1038/s41598-020-73242-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Guo Y, Czeyda-Pommersheim F, Miccio JA, Mahalingam S, Cecchini M, Pahade J. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection? Abdom Radiol (NY) 2021;46:5609-17. [PMID: 34557934 DOI: 10.1007/s00261-021-03284-5] [Reference Citation Analysis]
21 Lwin TM, Hoffman RM, Bouvet M. The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic. Expert Rev Anticancer Ther 2018;18:651-62. [PMID: 29768067 DOI: 10.1080/14737140.2018.1477593] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
22 Patel N, Petrinic T, Silva M, Soonawalla Z, Reddy S, Gordon-Weeks A. The Diagnostic Accuracy of Mutant KRAS Detection from Pancreatic Secretions for the Diagnosis of Pancreatic Cancer: A Meta-Analysis. Cancers (Basel). 2020;12. [PMID: 32825312 DOI: 10.3390/cancers12092353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kelly KN, Macedo FI, Seaton M, Wilson G, Hammill C, Martin RC, Maduekwe UN, Kim HJ, Maithel SK, Abbott DE, Ahmad SA, Kooby DA, Merchant NB, Datta J. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium. Ann Surg Oncol 2022. [PMID: 35511392 DOI: 10.1245/s10434-022-11804-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Malik AK, Robinson SM, French JJ, Sen G, Wilson CH, Hammond JS, White SA, Manas DM. Surgery for Hilar cholangiocarcinoma: the Newcastle upon Tyne Liver Unit experience. Eur Surg 2019;51:197-205. [DOI: 10.1007/s10353-019-0599-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Wei M, Gu B, Song S, Zhang B, Wang W, Xu J, Yu X, Shi S. A Novel Validated Recurrence Stratification System Based on 18F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer. Front Oncol 2021;11:650266. [PMID: 34055620 DOI: 10.3389/fonc.2021.650266] [Reference Citation Analysis]
26 Feng P, Cheng B, Wang ZD, Liu JG, Fan W, Liu H, Qi CY, Pan JJ. Application and progress of medical imaging in total mesopancreas excision for pancreatic head carcinoma. World J Gastrointest Surg 2021; 13(11): 1315-1326 [DOI: 10.4240/wjgs.v13.i11.1315] [Reference Citation Analysis]
27 Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
28 Wen C, Deng X, Ren D, Song X, Chen H, Wang J, Jin J, Cheng D, Xu Z, Zhang J, Xie J, Qi W, Gu J, Peng C, Chen D, Chen S, Shen B, Zhan Q. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Cancer Med 2020;9:7626-36. [PMID: 32862515 DOI: 10.1002/cam4.3425] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Ishido K, Kimura N, Wakiya T, Nagase H, Hara Y, Kanda T, Fujita H, Hakamada K. Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma. Ann Surg Oncol 2021. [PMID: 34608555 DOI: 10.1245/s10434-021-10866-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Hall WA, Goodman KA. Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. Radiat Oncol 2019;14:114. [PMID: 31242912 DOI: 10.1186/s13014-019-1277-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
31 Walston S, Salloum J, Grieco C, Wuthrick E, Diaz DA, Barney C, Manilchuk A, Schmidt C, Dillhoff M, Pawlik TM, Williams TM. Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation. Am J Clin Oncol 2018;41:1185-92. [PMID: 29727311 DOI: 10.1097/COC.0000000000000452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
32 Kaltenmeier C, Nassour I, Hoehn RS, Khan S, Althans A, Geller DA, Paniccia A, Zureikat A, Tohme S. Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study. J Gastrointest Surg 2020. [PMID: 33269460 DOI: 10.1007/s11605-020-04870-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Feng Z, Li K, Lou J, Ma M, Wu Y, Peng C. A Novel DNA Replication-Related Signature Predicting Recurrence After R0 Resection of Pancreatic Ductal Adenocarcinoma: Prognostic Value and Clinical Implications. Front Cell Dev Biol 2021;9:619549. [PMID: 33748108 DOI: 10.3389/fcell.2021.619549] [Reference Citation Analysis]
34 Tummers WS, Groen JV, Sibinga Mulder BG, Farina-Sarasqueta A, Morreau J, Putter H, van de Velde CJ, Vahrmeijer AL, Bonsing BA, Mieog JS, Swijnenburg RJ. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg. 2019;106:1055-1065. [PMID: 30883699 DOI: 10.1002/bjs.11115] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 21.0] [Reference Citation Analysis]
35 Patel AK, Rodríguez-López JL, Bahary N, Zureikat AH, Burton SA, Heron DE, Olson AC. Patterns of Failure After Adjuvant Stereotactic Body Radiation Therapy for Pancreatic Cancer With Close or Positive Margins. Adv Radiat Oncol 2020;5:1197-205. [PMID: 33305081 DOI: 10.1016/j.adro.2020.08.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, Burkhart RA, Rinkes IHMB, Molenaar IQ, Cameron JL, Weiss MJ, Wolfgang CL, He J. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Ann Surg. 2019;269:1154-1162. [PMID: 31082915 DOI: 10.1097/sla.0000000000002734] [Cited by in Crossref: 83] [Cited by in F6Publishing: 50] [Article Influence: 41.5] [Reference Citation Analysis]
37 Feng Z, Qian H, Li K, Lou J, Wu Y, Peng C. Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma. Front Mol Biosci 2021;8:676291. [PMID: 34095229 DOI: 10.3389/fmolb.2021.676291] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Birgin E, Rasbach E, Téoule P, Rückert F, Reissfelder C, Rahbari NN. Impact of intraoperative margin clearance on survival following pancreatoduodenectomy for pancreatic cancer: a systematic review and meta-analysis. Sci Rep 2020;10:22178. [PMID: 33335201 DOI: 10.1038/s41598-020-79252-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Erstad DJ, Sojoodi M, Taylor MS, Jordan VC, Farrar CT, Axtell AL, Rotile NJ, Jones C, Graham-O'Regan KA, Ferreira DS, Michelakos T, Kontos F, Chawla A, Li S, Ghoshal S, Chen YI, Arora G, Humblet V, Deshpande V, Qadan M, Bardeesy N, Ferrone CR, Lanuti M, Tanabe KK, Caravan P, Fuchs BC. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Clin Cancer Res 2020;26:5007-18. [PMID: 32611647 DOI: 10.1158/1078-0432.CCR-18-1359] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
40 Lu G, van den Berg NS, Martin BA, Nishio N, Hart ZP, van Keulen S, Fakurnejad S, Chirita SU, Raymundo RC, Yi G, Zhou Q, Fisher GA, Rosenthal EL, Poultsides GA. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study. Lancet Gastroenterol Hepatol 2020;5:753-64. [PMID: 32416764 DOI: 10.1016/S2468-1253(20)30088-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
41 Chopra A, Zenati M, Hogg ME, Zeh HJ 3rd, Bartlett DL, Bahary N, Zureikat AH, Beane JD. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer. Ann Surg Oncol 2021. [PMID: 34027585 DOI: 10.1245/s10434-021-10175-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Trestini I, Cintoni M, Rinninella E, Grassi F, Paiella S, Salvia R, Bria E, Pozzo C, Alfieri S, Gasbarrini A, Tortora G, Milella M, Mele MC. Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. World J Gastrointest Surg 2021; 13(9): 885-903 [PMID: 34621468 DOI: 10.4240/wjgs.v13.i9.885] [Reference Citation Analysis]
43 Jiang J, Ye S, Xu Y, Chang L, Hu X, Ru G, Guo Y, Yi X, Yang L, Huang D. Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer. Front Oncol 2020;10:1220. [PMID: 32850360 DOI: 10.3389/fonc.2020.01220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Nagakawa Y, Nakagawa N, Takishita C, Uyama I, Kozono S, Osakabe H, Suzuki K, Nakagawa N, Hosokawa Y, Shirota T, Honda M, Yamada T, Katsumata K, Tsuchida A. Reconsideration of the Appropriate Dissection Range Based on Japanese Anatomical Classification for Resectable Pancreatic Head Cancer in the Era of Multimodal Treatment. Cancers (Basel) 2021;13:3605. [PMID: 34298818 DOI: 10.3390/cancers13143605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Delpero JR, Sauvanet A. Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019. Front Oncol 2020;10:40. [PMID: 32117714 DOI: 10.3389/fonc.2020.00040] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
46 Ward EP, Zeh Iii HJ, Tsai S. Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer. Surg Oncol Clin N Am 2021;30:657-71. [PMID: 34511188 DOI: 10.1016/j.soc.2021.06.010] [Reference Citation Analysis]
47 Hu X, Xia F, Lee J, Li F, Lu X, Zhuo X, Nie G, Ling D. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma. Adv Sci (Weinh) 2021;8:2002545. [PMID: 33854877 DOI: 10.1002/advs.202002545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
48 Zang C, Li S, Chi B, Chen S, Ye Z. An intraductal papillary mucinous neoplasm associated tubular adenocarcinoma with sarcomatoid component: A case report. Radiol Case Rep 2021;16:3494-8. [PMID: 34539943 DOI: 10.1016/j.radcr.2021.08.040] [Reference Citation Analysis]
49 McIntyre CA, Zambirinis CP, Pulvirenti A, Chou JF, Gonen M, Balachandran VP, Kingham TP, D'Angelica MI, Brennan MF, Drebin JA, Jarnagin WR, Allen PJ. Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy. Ann Surg Oncol 2021;28:539-49. [PMID: 32451945 DOI: 10.1245/s10434-020-08600-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
50 Feng Z, Chen P, Li K, Lou J, Wu Y, Li T, Peng C. A Novel Ferroptosis-Related Gene Signature Predicts Recurrence in Patients With Pancreatic Ductal Adenocarcinoma. Front Mol Biosci 2021;8:650264. [PMID: 34631790 DOI: 10.3389/fmolb.2021.650264] [Reference Citation Analysis]
51 Wittmann D, Hall WA, Christians KK, Barnes CA, Jariwalla NR, Aldakkak M, Clarke CN, George B, Ritch PS, Riese M, Khan AH, Kulkarni N, Evans J, Erickson BA, Evans DB, Tsai S. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Front Oncol 2020;10:460. [PMID: 32351886 DOI: 10.3389/fonc.2020.00460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
52 Lambert A, Schwarz L, Ducreux M, Conroy T. Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. Cancers (Basel) 2021;13:4724. [PMID: 34572951 DOI: 10.3390/cancers13184724] [Reference Citation Analysis]
53 Kitahata Y, Kawai M, Hirono S, Okada KI, Miyazawa M, Motobayashi H, Ueno M, Hayami S, Miyamoto A, Yamaue H. Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy. Ann Surg Oncol 2021. [PMID: 34724126 DOI: 10.1245/s10434-021-10985-0] [Reference Citation Analysis]
54 Li S, Xu H, Wu C, Wang W, Jin W, Gao H, Li H, Zhang S, Xu J, Zhang W, Xu S, Li T, Ni Q, Yu X, Liu L. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Cancer Med 2019;8:572-84. [PMID: 30632317 DOI: 10.1002/cam4.1957] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
55 Baart VM, van Manen L, Bhairosingh SS, Vuijk FA, Iamele L, de Jonge H, Scotti C, Resnati M, Cordfunke RA, Kuppen PJK, Mazar AP, Burggraaf J, Vahrmeijer AL, Sier CFM. Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors. Mol Imaging Biol 2021. [PMID: 34642899 DOI: 10.1007/s11307-021-01657-2] [Reference Citation Analysis]
56 Felsenstein M, Lindhammer F, Feist M, Hillebrandt KH, Timmermann L, Benzing C, Globke B, Zocholl D, Hu M, Fehrenbach U, Sinn BV, Pelzer U, Sauer IM, Pratschke J, Malinka T. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? JCM 2022;11:2367. [DOI: 10.3390/jcm11092367] [Reference Citation Analysis]
57 Werthmann PG, Kempenich R, Lang-Avérous G, Kienle GS. Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with Viscum album extracts: A case report. World J Gastroenterol 2019; 25(12): 1524-1530 [PMID: 30948915 DOI: 10.3748/wjg.v25.i12.1524] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 van Dam MA, Vuijk FA, Stibbe JA, Houvast RD, Luelmo SAC, Crobach S, Shahbazi Feshtali S, de Geus-Oei LF, Bonsing BA, Sier CFM, Kuppen PJK, Swijnenburg RJ, Windhorst AD, Burggraaf J, Vahrmeijer AL, Mieog JSD. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Cancers (Basel) 2021;13:6088. [PMID: 34885196 DOI: 10.3390/cancers13236088] [Reference Citation Analysis]
59 Naumann P, Eberlein J, Farnia B, Liermann J, Hackert T, Debus J, Combs SE. Cachectic Body Composition and Inflammatory Markers Portend a Poor Prognosis in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation.Cancers (Basel). 2019;11. [PMID: 31717736 DOI: 10.3390/cancers11111655] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
60 Vega EA, Kutlu OC, Salehi O, James D, Alarcon SV, Herrick B, Krishnan S, Kozyreva O, Conrad C. Preoperative Chemotherapy for Pancreatic Cancer Improves Survival and R0 Rate Even in Early Stage I. J Gastrointest Surg. 2020;24:2409-2415. [PMID: 32394126 DOI: 10.1007/s11605-020-04601-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
61 Chiang CC, Yeh CT, Hwang TL, Chu YD, Lim SN, Chen CW, Kuo CJ, Le PH, Chen TH, Lin WR. The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma. J Clin Med 2019;8:E2225. [PMID: 31888240 DOI: 10.3390/jcm8122225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
62 Shah MM, Datta J, Merchant NB, Kooby DA. Landmark Series: Importance of Pancreatic Resection Margins. Ann Surg Oncol 2022;29:1542-50. [PMID: 34985731 DOI: 10.1245/s10434-021-11168-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Wang J, Lyu SC, Zhu JQ, Li XL, Lang R, He Q. Extended lymphadenectomy benefits patients with borderline resectable pancreatic head cancer-a single-center retrospective study. Gland Surg 2021;10:2910-24. [PMID: 34804879 DOI: 10.21037/gs-21-201] [Reference Citation Analysis]
64 Klaiber U, Roth S, Hackert T, Neoptolemos JP. Evolution of oncosurgical management of pancreatic cancer. Eur Surg 2019;51:165-73. [DOI: 10.1007/s10353-019-0587-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
65 Naumann P, Eberlein J, Farnia B, Hackert T, Debus J, Combs SE. Continued Weight Loss and Sarcopenia Predict Poor Outcomes in Locally Advanced Pancreatic Cancer Treated with Chemoradiation.Cancers (Basel). 2019;11. [PMID: 31126040 DOI: 10.3390/cancers11050709] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]